COL7

July 19, 2019

Transplants Using Patients’ Own Skin May Be Safe, Effective Treatment for RDEB, Trial Suggests

News

Transplanting a patient’s own healthy skin to treat their skin ulcers was found to be safe and effective for three people with recessive dystrophic epidermolysis bullosa (RDEB) for more ... Read more

November 12, 2018November 12, 2018

Intravenous Immunoglobulin and Rituximab Most Effective EBA Treatments, Study Reports

News

Treatment with intravenous immunoglobulin (IVIG) and off-label rituximab can lead to complete remission of epidermolysis bullosa acquisita (EBA), according to a study that also illustrates the variable clinical and immunological presentations ... Read more

October 29, 2018October 29, 2018

FDA Advises Fibrocell on Phase 3 Trial Design for FCX-007, Potential RDEB Therapy

News

Fibrocell Science has completed a type C meeting with the U.S. Food and Drug Administration in which they discussed the design of a Phase 3 clinical trial to assess the ... Read more

October 17, 2018October 17, 2018

First RDEB Adult Patients Do Well in Clinical Trial with Gene Therapy KB103

News

The first two adults with recessive dystrophic epidermolysis bullosa (RDEB) treated with the topical gene therapy candidate KB103 experienced increased levels of functional human collagen 7 (COL7) protein and anchoring ... Read more

August 1, 2018August 1, 2018

Blocking Inflammation-linked PI3K-Delta Molecule Could Lead to EBA Therapy, Mouse Study Suggests

News

Treatment targeting a specific molecule involved in inflammation — called PI3K-delta — eased skin lesions and prevented blistering in mouse models of epidermolysis bullosa acquisita (EBA), according to a ... Read more

May 23, 2018May 23, 2018

Positive Interim Results of Phase 1/2 Trial Support FCX-007 Gene Therapy for RDEB

News

FCX-007, an experimental gene therapy developed by Fibrocell Science in collaboration with Precigen (a subsidiary of Intrexon), continues to improve wound healing in recessive dystrophic epidermolysis bullosa (RDEB) patients, new ... Read more

May 14, 2018May 14, 2018

Krystal Biotech Doses First Patient in Phase 1/2 Trial Testing Gene Therapy Candidate KB103 for DEB

News

Krystal Biotech recently dosed the first patient in a Phase 1/2 clinical trial testing KB103, a topical gene therapy candidate for the treatment of dystrophic epidermolysis bullosa (DEB). DEB is ... Read more

April 23, 2018April 23, 2018

Krystal Biotech’s KB103 Receives Orphan Medicinal Product Designation in Europe

News

Krystal Biotech recently announced that the European Medicines Agency (EMA) has granted the company’s investigational therapy KB103 orphan medicinal product designation for the treatment of dystrophic epidermolysis bullosa (DEB). KB103 is ... Read more

March 28, 2018March 28, 2018

Krystal Files Application to Start Clinical Trial of Gene Therapy Candidate KB103

News

Krystal Biotech has submitted an investigational new drug application with the U.S. Food and Drug Administration (FDA) to start a Phase 1/2 clinical trial of its lead gene therapy candidate KB103 for ... Read more

February 5, 2018February 5, 2018

Study Finds New Gene Mutation Leading to Recessive Dystrophic Epidermolysis Bullosa

News

Japanese physicians have reported a newly discovered mutation in the COL7A1 gene, called c.6885_6898del14, which resulted in the development of recessive dystrophic epidermolysis bullosa (RDEB) in a child. The ... Read more

Pin It on Pinterest